Development of a potency assay for human dendritic cells: IL-12p70 production

Journal of Immunotherapy

Volumn 31, Issue 1, 2008, Pages 89-100

  Butterfield, Lisa H ^a   Gooding, William ^a   Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

DC1; Cancer vaccines; Dendritic cells; Interleukin 12; Potency assay

Indexed keywords

CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; INTERLEUKIN 12P70; CD40 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CELL MATURATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DRUG POTENCY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SIGNAL TRANSDUCTION; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE; CRYOPRESERVATION; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOASSAY; IMMUNOLOGY; METABOLISM; METHODOLOGY; MONOCYTE; MOUSE; TEMPERATURE; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CD40 LIGAND; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CRYOPRESERVATION; CULTURE MEDIA; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOASSAY; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-4; LIPOPOLYSACCHARIDES; MICE; MONOCYTES; REPRODUCIBILITY OF RESULTS; TEMPERATURE; TRANSFECTION; VIRAL VACCINES;

EID: 40749158781     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318158fce0     Document Type: Article

References (31)

1. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Immunity. 2003;15:138-147.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
3. Palucka AK, Laupeze B, Asporod C, et al. Immunotherapy via dendritic cells. Adv Exp Med Biol. 2005;560:105-114.
4. Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66:5910-5918.
5. Osada T, Clay TM, Woo CY, et al. Dendritic cell-based immunotherapy. Int Rev Immunol. 2006;25:377-413.
6. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091-5100.
7. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
8. McIlroy D, Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother. 2003;52:583-591.
9. Hoffmann TK, Muler-Berghaus J, Ferris RL, et al. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res. 2002;8:1787-1793.
10. Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-betal and interleukin-10. Blood. 2001;98:2992-2998.
11. Rughetti A, Pellicciotta I, Biffoni M, et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol. 2005;174:7764-7772.
12. de Vries IJ, Eggert AA, Scharenborg NM, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother. 2002;25:429-438.
13. Peng JC, Thomas R, Nielsen LK. Generation and maturation of dendritic cells for clinical applications under serum-free conditions. J Immunother. 2005;28:599-609.
14. Elias M, van Zanten J, Hospers G, et al. Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy. J Clin Apher. 2005;20:197-207.
15. Tuyaerts S, Noppe SM, Corthals J, et al. Generations of large numbers of dendritic cells in a closed system using cell factories. J Immunol Meth. 2002;264:135-151.
16. Whiteside TL, Stanson J, Shurin MR, et al. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol. 2004;173:1526-1534.
17. Morel S, Levy F, Burlet-Schiltz O, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 2000;12:107-117.
18. Williams MA, Porter M, Horton M, et al. Ambient particulate matter directs nonclassic dendritic cell activation and a mixed TH1/ TH2-like cytokine response by naïve CD4+T cells. J Allergy Clin Immunol. 2007;119:488-497.
19. Wesa A, Kalinski P, Kirkwood JM, et al. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother. 2007;30:75-82.
20. Hilkens CM, Kalinski P, de Boer M, et al. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood. 1997;90:1920-1926.
21. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003;19:641-644.
22. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133-146.
23. Keisall BL, Stuber E, Neurath M, et al. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann NY Acad Sci. 1996;795:116-126.
24. Santini SM, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med. 2000;191:1777-1788.
25. Hokey DA, Larregina AT, Erdos G, et al. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 2005;65:10059-10067.
26. Snijders A, Kalinski P, Hilkens CM, et al. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol. 1998;10:1593-1598.
27. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
28. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934-5937.
29. Quan H, Shih W. Assessing reproducibility by the within-subject coefficient of variation with random effects models. Biometrics. 1996;52:1195-1203.
30. Kalinski P, Vieira PL, Schuitemaker JH, et al. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001;97:3466-3469.
31. Whiteside TL. Cytokine assays. Biotechniques. 2002;33:4-15.